Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders

Neurology

Volumn 83, Issue 11, 2014, Pages 990-995

  Lattante, Serena ^a   Millecamps, Stéphanie ^a   Stevanin, Giovanni ^a,b   Rivaud Péchoux, Sophie ^a   Moigneu, Carine ^a   Camuzat, Agnès ^a   Da Barroca, Sandra ^a   Mundwiller, Emeline ^a   Couarch, Philippe ^a   Salachas, François ^b   Hannequin, Didier ^c   Meininger, Vincent ^b   Pasquier, Florence ^d   Seilhean, Danielle ^b   Couratier, Philippe ^e   Danel Brunaud, Véronique ^f   Bonnet, Anne Marie ^b   Tranchant, Christine ^g   Le Guern, Eric ^b   Brice, Alexis ^a,b   Le Ber, Isabelle ^a,b   Kabashi, Edor ^a   more..

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

^d UNIV LILLE   (France)

^e UNIVERSITÉ DE LIMOGES   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLUTAMINE; C9ORF72 PROTEIN, HUMAN; NERVE PROTEIN; PEPTIDE; PROTEIN; REPETITIVE DNA; SCA2 PROTEIN;

ALLELE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATXN2 GENE; C9ORF72 GENE; COHORT ANALYSIS; CONTROLLED STUDY; FRONTOTEMPORAL DEMENTIA; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MODIFIER GENE; OPEN READING FRAME; PATHOGENICITY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; FRANCE; GENETIC PREDISPOSITION; GENETICS; NUCLEOTIDE SEQUENCE; RISK FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DNA REPEAT EXPANSION; FRANCE; FRONTOTEMPORAL DEMENTIA; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; NERVE TISSUE PROTEINS; PEPTIDES; PROTEINS; RISK FACTORS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84908320047     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000778     Document Type: Article

References (36)

1. Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediatelength polyglutamine expansions are associated with increased risk for ALS. Nature 2010;466:1069-1075.
2. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
3. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
4. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDSSPSP international workshop. Neurology 1996;47:1-9.
5. Le Ber I, van der Zee J, Hannequin D, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 2007;28:846-855.
6. Le Ber I, Camuzat A, Guillot-Noel L, et al. C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis 2013;34:485-499.
7. Lattante S, Le Ber I, Camuzat A, Brice A, Kabashi E. Mutations in the PFN1 gene are not a common cause in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration in France. Neurobiol Aging 2013;34:1709.
8. Lattante S, Le Ber I, Camuzat A, et al. Screening UBQLN-2 in French frontotemporal lobar degeneration and frontotemporal lobar degeneration-amyotrophic lateral sclerosis patients. Neurobiol Aging 2013;34:2078.
9. Le Ber I, Camuzat A, Guerreiro R, et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol 2013;70:1403-1410.
10. Lattante S, Le Ber I, Camuzat A, et al. TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia. Neurobiol Aging 2013;34:2443.
11. Millecamps S, Boillée S, Le Ber I, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALSrelated genes. J Med Genet 2012;49:258-263.
12. Millecamps S, Salachas F, Cazeneuve C, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet 2010;47:554-560.
13. Millecamps S, Boillée S, Chabrol E, et al. Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiol Aging 2011;32:557.
14. Teyssou E, Takeda T, Lebon V, et al. Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol 2013;125:511-522.
15. Millecamps S, Corcia P, Cazeneuve C, et al. Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. Neurobiol Aging 2012;33:839.
16. Teyssou E, Vandenberghe N, Moigneu C, et al. Genetic analysis of SS18L1 in French amyotrophic lateral sclerosis. Neurobiol Aging 2014;35:1213.
17. Van Damme P, Veldink JH, van Blitterswijk M, et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011;76:2066-2072.
18. Cancel G, Dürr A, Didierjean O, et al. Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum Mol Genet 1997;6:709-715.
19. Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996;14:269-276.
20. Farg MA, Soo KY, Warraich ST, Sundaramoorthy V, Blair IP, Atkin JD. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum Mol Genet 2013;22:717-728.
21. Corrado L, Mazzini L, Oggioni GD, et al. ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet 2011;130:575-580.
22. Daoud H, Belzil V, Martins S, et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol 2011;68:739-742.
23. Lee T, Li YR, Chesi A, et al. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 2011;76:2062-2065.
24. Ross OA, Rutherford NJ, Baker M, et al. Ataxin-2 repeatlength variation and neurodegeneration. Hum Mol Genet 2011;20:3207-3212.
25. Sorarù G, Clementi M, Forzan M, et al. ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology 2011;76: 2030-2031.
26. Yu Z, Zhu Y, Chen-Plotkin AS, et al. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One 2011;6:e17951.
27. Conforti FL, Spataro R, Sproviero W, et al. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology 2012;79:2315-2320.
28. Gispert S, Kurz A, Waibel S, et al. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 2012;45:356-361.
29. Gellera C, Ticozzi N, Pensato V, et al. ATAXIN2 CAGrepeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiol Aging 2012; 33:1847.e15-21.
30. Lattante S, Conte A, Zollino M, et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology 2012;79:66-72.
31. Van Langenhove T, van der Zee J, Engelborghs S, et al. Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiol Aging 2012;33:1004.
32. Liu X, Lu M, Tang L, Zhang N, Chui D, Fan D. ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging 2013;34:2236.e5-8.
33. Yamashita C, Tomiyama H, Funayama M, et al. The evaluation of polyglutamine repeats in autosomal dominant Parkinson's disease. Neurobiol Aging 2014;35:1779.e17-21.
34. Charles P, Camuzat A, Benammar N, et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology 2007;69:1970-1975.
35. van Blitterswijk M, van Es MA, Hennekam EA, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 2012;21:3776-3784.
36. van Blitterswijk M, DeJesus-Hernandez M, Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Curr Opin Neurol 2012;25:689-700.